Literature DB >> 3275865

Complex translocation disrupts c-myc regulation in a human plasma cell myeloma.

G F Hollis1, A F Gazdar, V Bertness, I R Kirsch.   

Abstract

A complex translocation has interrupted the third exon of the c-myc gene in human plasma cell myeloma tumor cells and a derivative cell line (NCI-H929). As a result of this rearrangement, a chimeric mRNA is expressed which commences 5' of the c-myc coding region and includes sequences introduced by the translocation event. All of the detectable c-myc-containing mRNA in the tumor and cell line was derived from this rearranged c-myc allele. This chimeric c-myc mRNA, in which most of the germ line c-myc 3' untranslated region has been replaced, was greater than sevenfold more stable than c-myc transcripts with intact 3' ends. This suggests that the 3' untranslated region may play an important role in c-myc mRNA stability.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3275865      PMCID: PMC363091          DOI: 10.1128/mcb.8.1.124-129.1988

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  25 in total

Review 1.  Transcription termination and 3' processing: the end is in site!

Authors:  M L Birnstiel; M Busslinger; K Strub
Journal:  Cell       Date:  1985-06       Impact factor: 41.582

2.  Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene.

Authors:  A F Gazdar; H K Oie; I R Kirsch; G F Hollis
Journal:  Blood       Date:  1986-06       Impact factor: 22.113

Review 3.  Oncogenes in B-cell neoplasia.

Authors:  M Potter; J F Mushinski
Journal:  Cancer Invest       Date:  1984       Impact factor: 2.176

4.  Altered nucleotide sequences of a translocated c-myc gene in Burkitt lymphoma.

Authors:  T H Rabbitts; P H Hamlyn; R Baer
Journal:  Nature       Date:  1983 Dec 22-1984 Jan 4       Impact factor: 49.962

5.  Activation and somatic mutation of the translocated c-myc gene in burkitt lymphoma cells.

Authors:  R Taub; C Moulding; J Battey; W Murphy; T Vasicek; G M Lenoir; P Leder
Journal:  Cell       Date:  1984-02       Impact factor: 41.582

6.  Extreme instability of myc mRNA in normal and transformed human cells.

Authors:  C Dani; J M Blanchard; M Piechaczyk; S El Sabouty; L Marty; P Jeanteur
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

7.  Amplification of the c-myc oncogene in human plasma-cell leukemia.

Authors:  J Sümegi; T Hedberg; M Björkholm; T Godal; H Mellstedt; M G Nilsson; C Perlman; G Klein
Journal:  Int J Cancer       Date:  1985-09-15       Impact factor: 7.396

8.  Posttranscriptional mechanisms are responsible for accumulation of truncated c-myc RNAs in murine plasma cell tumors.

Authors:  M Piechaczyk; J Q Yang; J M Blanchard; P Jeanteur; K B Marcu
Journal:  Cell       Date:  1985-09       Impact factor: 41.582

9.  Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma.

Authors:  P G Pelicci; D M Knowles; I Magrath; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

10.  Variant (6;15) translocations in murine plasmacytomas involve a chromosome 15 locus at least 72 kb from the c-myc oncogene.

Authors:  S Cory; M Graham; E Webb; L Corcoran; J M Adams
Journal:  EMBO J       Date:  1985-03       Impact factor: 11.598

View more
  16 in total

Review 1.  MRNA stability and the control of gene expression: implications for human disease.

Authors:  Elysia M Hollams; Keith M Giles; Andrew M Thomson; Peter J Leedman
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

2.  Expression, regulation, and chromosomal localization of the Max gene.

Authors:  A J Wagner; M M Le Beau; M O Diaz; N Hay
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

3.  Rapid c-myc mRNA degradation does not require (A + U)-rich sequences or complete translation of the mRNA.

Authors:  I A Laird-Offringa; P Elfferich; A J van der Eb
Journal:  Nucleic Acids Res       Date:  1991-05-11       Impact factor: 16.971

Review 4.  RNA surveillance: molecular approaches in transcript quality control and their implications in clinical diseases.

Authors:  Karen C M Moraes
Journal:  Mol Med       Date:  2009-10-07       Impact factor: 6.354

Review 5.  The complex world of post-transcriptional mechanisms: is their deregulation a common link for diseases? Focus on ELAV-like RNA-binding proteins.

Authors:  Alessia Pascale; Stefano Govoni
Journal:  Cell Mol Life Sci       Date:  2011-09-10       Impact factor: 9.261

6.  Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.

Authors:  Y Shou; M L Martelli; A Gabrea; Y Qi; L A Brents; A Roschke; G Dewald; I R Kirsch; P L Bergsagel; W M Kuehl
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

7.  Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 (vIRF4) targets expression of cellular IRF4 and the Myc gene to facilitate lytic replication.

Authors:  Hye-Ra Lee; Sultan Doğanay; Brian Chung; Zsolt Toth; Kevin Brulois; Stacy Lee; Zhansaya Kanketayeva; Pinghui Feng; Taekjip Ha; Jae U Jung
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

8.  Molecular genetic analysis of lymphoid tumors arising after organ transplantation.

Authors:  J Locker; M Nalesnik
Journal:  Am J Pathol       Date:  1989-12       Impact factor: 4.307

9.  AUUUA is not sufficient to promote poly(A) shortening and degradation of an mRNA: the functional sequence within AU-rich elements may be UUAUUUA(U/A)(U/A).

Authors:  C A Lagnado; C Y Brown; G J Goodall
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

10.  Epidermal growth factor increases the interaction between nucleolin and heterogeneous nuclear ribonucleoprotein K/poly(C) binding protein 1 complex to regulate the gastrin mRNA turnover.

Authors:  Pin-Tse Lee; Pao-Chi Liao; Wen-Chang Chang; Joseph T Tseng
Journal:  Mol Biol Cell       Date:  2007-10-10       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.